background: Preimplantation cross-talk between a functional blastocyst and the endometrium is critical for successful blastocyst implantation. This interaction is mediated in part by endometrial cytokines/growth factors secreted by glandular epithelium into the uterine cavity. Recent evidence suggests that blastocyst-derived hCG may influence the endometrial milieu in conception cycles thereby enhancing receptivity and implantation success. This study investigated the effect of hCG on the secretory profile of a select cohort of 44 cytokines/growth factors from primary human endometrial epithelial cells (hEECs). These factors included those with both known and unknown roles during receptivity and implantation. The expression of one previously unknown hCG-regulated factor, fibroblast growth factor 2 (FGF2), in human endometrium and its effects on hEEC function were further examined.
Introduction
Blastocyst implantation begins with apposition and attachment of the blastocyst to the endometrium, specifically to the luminal epithelium lining the uterine cavity. This is followed by invasion of the trophoblast cells of the conceptus into the endometrium. For most of the cycle, the endometrium is retained in a non-receptive/refractory state and will only support implantation during a discrete period in the mid-secretory phase of the cycle ( 6-9 days following the LH peak; Psychoyos, 1973) . This is referred to as the 'period of endometrial receptivity' or 'window of implantation'. Its onset is characterized by the differentiation of the endometrial glandular epithelium into a highly secretory state and the production of numerous cytokines and growth factors that facilitate implantation .
Successful implantation requires the coordinated cross-talk between a functional blastocyst and a 'receptive' endometrium. The blastocyst itself secretes various factors that facilitate this cross-talk. HCG, a glycoprotein hormone, is one of the earliest blastocystderived signals received by the endometrium (Bonduelle et al., 1988) . It is transcribed as early as the 2-cell embryo stage (Jurisicova et al., 1999) and is produced abundantly by the trophectodermal cells of the preimplantation blastocyst (Lopata and Hay, 1989) . Following implantation, hCG is produced by syncytiotrophoblast of the developing conceptus (Hoshina et al., 1985) and its primary role is the maintenance of progesterone production by the corpus luteum. Recent evidence suggests that hCG is also produced by the human endometrium, maximally by endometrial epithelial cells during the secretory phase (Zimmermann et al., 2009) .
hCG/LH-receptor (R) mRNA and protein are also expressed in human endometrium, with maximal expression in epithelial cells during the secretory phase (Reshef et al., 1990; Licht et al., 2003; Perrier d'Hauterive et al., 2004 . hCG/LH-R is likewise detected in primary human endometrial epithelial cells (hEECs) in vitro (Zhou et al., 1999; Perrier d'Hauterive et al., 2004) . Emerging evidence suggests a local/paracrine role for hCG in endometrial differentiation and receptivity that precedes its classical endocrine role (Fazleabas et al., 1999) . In models of early human pregnancy, hCG stimulates endometrial production of leukaemia inhibitory factor (LIF), a cytokine critical for implantation in mice and vascular endothelial growth factor (VEGF), a pro-angiogenic factor, both in vivo (Licht et al., 1998) and in primary hEEC in vitro (Perrier d 'Hauterive et al., 2004; Berndt et al., 2006) . hCG also inhibits macrophage colony-stimulating factor (MCSF) and insulin-like growth factor-binding protein 1 production in vivo (Licht et al., 1998) , and it inhibits interleukin-6 (IL6) production by primary hEEC in vitro (Perrier d'Hauterive et al., 2004) . Whether hCG regulates other endometrial cytokines and growth factors important for receptivity is unknown.
In this study, we further explored the hypothesis that hCG modulates human endometrial receptivity during blastocyst implantation. We established a secretory profile of a selected cohort of 44 cytokines and growth factors with known and unknown roles during receptivity and implantation produced by primary hEEC in vitro, and determined the effect of hCG on their production. We further investigated the expression of one previously unknown hCG-regulated factor, fibroblast growth factor 2 (FGF2), in hEEC in vivo and its effects on hEEC functions associated with endometrial receptivity.
Materials and Methods

Tissue collection
Ethical approval was obtained from the appropriate institutional ethics committees. Written informed consent was obtained from all participants. Endometrial tissue was obtained by dilatation and curettage from women with no known endometrial abnormalities, undergoing minor gynaecological surgical procedures, such as laparoscopic sterilization or investigation of tubal patency. All women had regular menstrual cycles and no steroid treatment for at least 2 -3 months before collection of tissue. Endometrial samples (n ¼ 15) were collected from the proliferative [Day (d) 6 -10] and secretory phases (d15 -26) of the menstrual cycle. Stage of cycle was confirmed by histological assessment by experienced pathologists according to the criteria of (Noyes et al., 1975) . Placental samples (6-10 weeks pregnancy; n ¼ 5) were collected from healthy women undergoing first trimester suction-termination of pregnancy (6-10 weeks) for psychosocial reasons. Tissues for immunohistochemistry were washed in 0.9% saline before transfer to 4% neutral buffered formalin solution, with subsequent processing to wax. Tissues for cell culture were transferred to a 1:1 mixture of DMEM and Ham's F-12 (DMEM/F12; Thermo Electron Corp., Melbourne, Australia) before cell isolation.
Primary hEECs
hEECs were isolated from endometrial tissues from the secretory phase (d18 -26) as described previously (Marwood et al., 2009) . Briefly, endometrial samples were digested with collagenase type 3 (45 U/ml; Worthington Biochemical Corp., Lakewood, NJ, USA) and DNase 1 (2000 U/ml; Roche, Castle Hill, NSW, Australia) and the suspension was filtered through 43 and 11 mm nylon mesh to harvest the endometrial epithelial glands. The cells/epithelial fragments were collected, resuspended and plated in a Dulbecco's modified Eagle's medium (DMEM)/ F12 (Thermo Electron Corp.) supplemented with 10% fetal calf serum (FCS; Invitrogen, Carlsbad, CA, USA), 2 mM L-glutamine (Thermo Electron Corp.) and 1% antibiotic -antimycotic solution (Life Technologies, Inc., Auckland, New Zealand). Epithelial glands were collected from the filter paper and further purified through selective adherence. Briefly, epithelial glands were serially replated (three times) in plastic culture dishes for 30 min to allow adherence of contaminating stromal cells. Nonadherent hEEC/glands were transferred to 24-well plates and hEECs were allowed to grow out from glandular structures for 48 h. A purity of .95% was required for the cells to be used experimentally. Cell purity was tested routinely by immunostaining for cytokeratin as described previously (Marwood et al., 2009) . Confluent hEECs were transferred to serum-free DMEM/F12, 2 mM L-glutamine (all from Thermo Electron Corp.), and 1% antibiotic -antimycotic solution containing transferrin (10 mg/ml; Sigma Chemical Company, St. Louis, MO, USA), sodium selenite (25 ng/ml; Sigma) and linoleic acid (10 nmol/l; Sigma; DMEM/ F12-TSL; Dimitriadis et al., 2002; Marwood et al., 2009) and treated in duplicate with or without recombinant hCG (NIDDK, National Hormone and Peptide program, USA; 0.2 -20 IU/ml) for 48 h. The doses of hCG used were selected from previous publications (Perrier d'Hauterive et al., 2004; Evans et al., 2009) . At the end of the experiment, conditioned media from duplicate wells were pooled and protein was extracted from the cells to assess total protein to represent cell number per well.
Endometrial epithelial cell line
We used the hEEC line (ECC-1) (a gift from Professor Bruce Lessey, Center for Women's Medicine, Division of Reproductive Endocrinology and Infertility, Greenville Hospital System, Greenville, SC, USA), which has been well-characterized previously and in our laboratory (Mo et al., 2006; Kaitu'u-Lino et al., 2007; Hannan et al., 2009 Hannan et al., ,2010 Media from placental explants in culture were included both as quality control (to monitor reproducibility) and as positive control samples. The lower detection limit of the assay was 0.8 mIU/ml, and inter-and intra-assay variability was 8.6 and 6%, respectively.
Milliplex
TM Luminex TM multiplex assays
The production of 44 cytokines and growth factors by primary hEECs was analysed using quantitative Milliplex TM cytokine assays based on xMAP technology (Luminex; Austin, TX, USA). A multiplex panel was used to simultaneously quantify 42 cytokines/growth factors (Table I ; Milliplex Human Cytokine 42-plex pre-mixed; Millipore, Melbourne, Australia). LIF and IL11 (of special interest to our laboratory) were analysed separately using a 1-plex assay (Millipore) as they showed cross-reactivity with the antibodies in the 42-plex panel. The Luminex analyses were performed in duplicate according to manufacturer's instructions. To avoid the effect of inter-assay variation, all samples compared statistically were analysed on the same plate. The lower detection limit was 4 pg/ml for all analytes and intra-assay variability was ,10%. Data were collected and analysed using a BioPlex 200 instrument equipped with BioManager analysis software (BioRad). Test runs were performed before analyses of the included samples to optimize the Luminex analyses (i.e. dilution of samples).
Immunohistochemistry
Immunohistochemistry for FGF2 was performed on endometrial tissues from both the proliferative (d6-10; n ¼ 5) and mid-late secretory (d19 -26; n ¼ 5) phases of the menstrual cycle and first trimester pregnancy endometrium (6-10 weeks; n ¼ 5). Paraffin sections (5 mm) were dewaxed in Histosol (Sigma) and rehydrated through descending grades of alcohol to H 2 O. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide. Tissues were incubated with non-immune block (10% normal horse serum; 2% normal human serum) for 30 min, followed by rabbit anti-human FGF2 (2.5 mg/ml; Abcam, Cambridge, MA, USA #65973) or non-immune rabbit IgG (negative control) at 48C for 16 h, followed by biotinylated goat anti-rabbit IgG (1:200; Vector Laboratories Inc., Burlingame, CA, USA) for 30 min, and streptavidin-biotin -peroxidase complex ABC (DakoCytomation, Glostrup, Denmark). FGF2 protein was visualized as a brown precipitate using diaminobenzidine tetrahydrochloride substrate (DakoCytomation). Sections were rinsed and mounted using DEPX.
Staining was examined with an Olympus CH30 microscope (Melville, NY, USA) and high resolution images were captured with an Hc-2000 digital camera (Fujix, Tokyo, Japan). Positive immunostaining in each cellular compartment was scored by two independent observers blind to the nature of the tissue. Staining was allocated a score from 0 to 3 with 0.5 increments where 0 is no staining and 3 is intense staining. Four visual fields were evaluated per sample. The final score was based on an average of the two individual scores. For the purposes of this study only the amount of staining in glandular epithelium is reported. 
SDS -PAGE and western blotting
To investigate whether hEECs were biologically responsive to FGF2, the effects of FGF2 on phosphorylation of the downstream signalling molecules ERK1/2 in ECC-1 cells was investigated. ECC-1 cells were grown to confluence, transferred to serum-free DMEM/F12-TSL for 24 h and then treated with rhFGF2 (R&D Systems Incorp., Minneapolis, MN, USA) at 1, 10, 100 ng/ml or vehicle (in experimental medium) for 5 min. The experiment was repeated twice and cellular protein was extracted and protein concentration was quantified as above. Samples of 30 mg of protein were resolved on 10% SDS -PAGE gels, transferred to nitrocellulose membranes, blocked with 5% non-fat dry milk in trisbuffered saline (TBS)/0.1% Tween 20 (Bio-Rad, Regent's Park, NSW, Australia) and probed separately with monoclonal antibodies against phospho (Thr 202/Tyr 204) ERK1/2 (1:1000) or total ERK1/2 (1:10 000; Cell Signaling Technology Inc., Beverly, MA, USA) overnight at 48C. The membranes were washed in TBS/0.1% Tween 20 (Bio-Rad) and incubated for 1 h with horse-radish peroxidase (HRP)-conjugated rabbit secondary antibody (1:1500; DakoCytomation, Glostrup, Denmark). HRP activity was detected using enhanced chemiluminescence reagent (Pierce Biotechnology Inc., Rockford, IL, USA). Membranes were exposed to autoradiographic film (GE Healthcare Bio-Sciences Pty. Ltd, Rydalmere, NSW, Australia) with the exposure time adjusted to maintain the integrated OD within a linear and non-saturated range. Densitometric analysis of band intensity was performed using Gel Doc (Bio-Rad). All western blots were carried out in duplicate.
Adhesion assays
To investigate the potential actions of FGF2 in hEEC functions associated with endometrial receptivity, we examined the effects of FGF2 on ECC-1 cell adhesion to the extracellular matrix (ECM) components, fibronectin (FN) and collagen type IV that are associated with the trophectoderm of the blastocyst (Thorsteinsdottir, 1992; Shimomura et al., 2006) . Adhesion of ECC-1 cells to ECM components was determined using commercially available cell-adhesion assay kits (Cytomatrix TM Screening Kit, Millipore) according to manufacturer's instructions. These kits comprised of 96-well plates coated with ECM substrates, FN and collagen type IV (COLIV). ECC-1 cells were grown to 50% confluence, transferred to DMEM/F12-TSL for 24 h and then treated with rhFGF2 (100 ng/ml) or vehicle (in experimental medium) for 48 h. Cells were then detached, washed twice with PBS, resuspended thoroughly in serum-free media (to avoid clumping of cells) and seeded in ECM-coated wells at a density of 5 × 10 4 cells/well in 100 ml serum-free media (4-6 wells/ ECM per treatment) for 1.5 h at 378C in a CO 2 incubator. Wells were washed with PBS to eliminate non-adhered cells, stained with 0.2% crystal violet solution in 10% ethanol for 5 min at room temperature, washed again with PBS (to eliminate unincorporated crystal violet) and the cell-bound stain was solubilized with 100 ml solubilization buffer (a 50/50 mixture of 0.1 M NaH 2 PO 4 , pH 4.5 and 50% ethanol) for 5 min at room temperature with shaking. Absorbance (representing the number of adhered cells) was measured at 540 -570 nm. BSA-coated wells were included for each treatment as negative controls. The entire experiment was repeated twice.
Statistical analysis
Data are expressed as mean + SEM for treatment compared with control. Statistical analysis was performed on raw data by a paired Student's t-test or one-way or two-way analysis of variance followed by Tukey's post hoc test (P , 0.05 taken as significant) after testing for normal distribution using PRISM version 3.00 for Windows (GraphPad). If data were not normally distributed, they were log transformed before statistical analysis.
Results
Secretory profile of primary hEECs under basal conditions
Primary hEEC did not secrete hCG under the culture conditions used. Of the 44 analytes examined all but five were detectable in hEEC secretions (Table I ). These could be broadly separated into four groups according to their concentrations in epithelial cell secretions expressed as pg/mg total protein (i.e. ,1 pg/mg; 1 -10 pg/mg, 10 -100 pg/mg, 100 to .1000 pg/mg). Ten factors including PDGFA, TNFB, sIL2RA, IL1B, FLT3L, IFNG, sCD40L, IL12p40, IL7 and IFNA2 were identified for the first time as being produced by hEECs. The concentrations of these were all ,10 pg/mg in hEEC secretions.
Effect of hCG on primary endometrial epithelial production of cytokines/growth factors Treatment of primary endometrial epithelial cells with hCG (2 IU/ml) significantly stimulated the production of 6 out of 44 analytes (versus control) IL11 (64 + 24%), GMCSF (45 + 12%), CXCL10 (69 + 24%), FGF2 (52 + 23%) as well as VEGF (102 + 57%) and LIF (88 + 52%) both of which acted as positive controls (n ¼ 8; P , 0.05; Figs 1 and 2). The concentrations of these analytes were all .10 pg/mg in Figure 1 Treatment of primary hEECs with hCG (2 IU/ml) significantly stimulated the production of VEGF and LIF (both positive controls) and IL11, GMCSF, CXCL10 and FGF2 (combined data from n ¼ 8 separate cell cultures; *P , 0.05, **P , 0.01 versus control).
hEEC secretions (Table I) . Further, these effects of hCG occurred in a dose-dependent manner (Fig. 2) , with no effect of hCG at the lower dose of 0.2 IU/ml but an increase observed at 2 and 20 IU/ml for all factors [i.e. IL11 ( Fig. 2A) , GMCSF ( Fig. 2B ) and FGF2 ( Fig. 2D) ] except CXCL10 (Fig. 2C ).
FGF2 expression and actions in human endometrial epithelium
Since previous data on the expression of FGF2 in the human endometrium was conflicting (Ferriani et al., 1993; Moller et al., 2001) we examined the cellular localization of FGF2 in human endometrium across the menstrual cycle and in first trimester pregnancy decidua with a particular focus on the glandular epithelium. We also examined whether FGF2 was biologically active in hEEC cells and its potential actions on these cells with regard to endometrial receptivity.
Epithelial FGF2 is expressed maximally in secretory phase and first trimester pregnancy endometrium
Faint FGF2 staining was observed localized to stroma in proliferative phase endometrium, with little or no staining observed in glandular and luminal epithelium (Fig. 3A) . In mid-secretory phase endometrium, FGF2 strongly localized to stroma and blood vessels (Fig. 3B) . FGF2 also localized to glandular epithelium (Fig. 3B) . However, this was variable, with some glands staining positive for FGF2 whereas others were negative (arrowheads). In first trimester pregnancy decidua, FGF2 was intensely localized to all cellular compartments including glandular epithelium and decidualized stroma (Fig. 3C ). Semiquantitative scoring of immunoreactive FGF2 in glandular epithelium indicated increased staining across the menstrual cycle (Fig. 3D) , with FGF2 being low in the proliferative phase and 8-fold higher in the secretory phase (P , 0.001) and first trimester pregnancy endometrium (P , 0.001).
FGF2 stimulates phosphorylation of ERK1/2 in ECC-1 cells
To determine whether ECC-1 cells could respond to FGF2, phosphorylation of the downstream signalling molecules ERK1/2 was examined. FGF2 stimulated phosphorylation (p) of ERK1/2 in ECC-1 cells but had no effect on ERK1/2 abundance (Fig. 4) . pERK1/2 was detectable at low levels following vehicle-treatment but was significantly up-regulated following FGF2 treatment (5 min) at doses of 1, 10 and 100 ng/ml (P , 0.05; Fig. 4 ).
FGF2 stimulates ECC-1 cell-ECM interactions
Treatment of ECC-1 cells with FGF2 (100 ng/ml) for 48 h significantly increased ECC-1 binding to both FN (362 + 21%; P , 0.01) and collagen IV (COL IV) (391 + 24%); P , 0.01) compared with controls (Fig. 5) . (combined data from n ¼ 7 separate cultures, *P , 0.05 versus control). hCG had no effect at the lower dose of 0.2 IU/ml but significantly stimulated the production of all four analytes at 2 IU/ml and all but CXCL10 at 20 IU/ml. hCG enhances endometrial receptivity
Discussion
The results of this study provide further evidence for a role for hCG in selectively modulating endometrial production of cytokines and growth factors important for human endometrial receptivity during implantation. It also introduces a novel role for FGF2 in human endometrial receptivity. For the first time, hCG was demonstrated to regulate the production of four proteins: IL11, CXCL10, GMCSF and FGF2 by primary hEEC. Although these factors have been previously identified in human endometrium, their regulation by hCG was not known. hCG also regulated VEGF and LIF as previously described (Licht et al., 1998; Perrier d'Hauterive et al., 2004; Berndt et al., 2006) , which validated this study. FGF2 expression in human endometrial glandular epithelium in vivo increased as the menstrual cycle progressed from the proliferative to secretory phase, and remained high in first trimester pregnancy endometrium. FGF2 was also biologically and functionally active in ECC-1 cells stimulating phosphorylation of ERK1/2 in ECC-1 cells in vitro and their adhesion to the ECM components FN and collagen IV, which are associated with the trophectoderm of blastocyst (Thorsteinsdottir, 1992; Shimomura et al., 2006) . Finally, a secretory profile of 44 cytokines/growth factors produced by primary hEEC was established. Ten of these factors were identified in primary hEEC for the first time.
Our studies confirm and extend in vivo results (Licht et al., 2001b) in which increased LIF and VEGF levels in uterine fluid were observed following microdialysis of the uterine cavity with 50 IU hCG per hour. They also confirm previous in vitro results where hCG was shown to induce LIF production by primary hEEC (Perrier d'Hauterive et al., 2004) . Although other studies observed an increase in IL6 production by primary hEEC as a result of hCG stimulation (Uzumcu et al., 1998; Perrier d'Hauterive et al., 2004) , IL6 was unaffected by hCG in the present study. This discrepancy could be dose-dependent as the doses of hCG used in these studies were higher (.2 IU/ml) than in the present study. However, the responses of the other cytokines investigated suggest that the doses used in the present study were appropriate. To our knowledge, there is no information on hCG levels in uterine flushings during preimplantation development. However, hCG has been measured in culture medium from Day 5 embryos with a range of 0.8 -6.2 mIU/ml, and mean of 1.61 + 0.3 mIU/ml (Oum et al., 2006) . Importantly, the blastocyst is in very close proximity to the endometrial surface and the total volume of fluid within the area is likely no more than 1-2 ml. Therefore, what is measured as mIU/ml would be concentrated 1000-fold. This brings the dose ranges used in our study (0.2 -20 IU), which were based on other cell culture studies as cited, within the physiological range.
Importantly, the secretory profile of factors in endometrial epithelial secretions closely paralleled that of uterine lavage fluid . Those analytes that were abundant in uterine lavage fluid (e.g. CXCL10, GMCSF and CXCL1-3) were produced at high levels in endometrial epithelial cell secretions and vice versa.
The hCG-regulated cytokines CXCL10, GMCSF, IL11 and FGF2 are all expressed by human endometrial glandular and luminal epithelium in vivo, with immunoreactive CXCL10, GMCSF and IL11 reaching maxima during the secretory/receptive phase (Tabibzadeh and Sun, 1992; Ferriani et al., 1993; Giacomini et al., 1995; Zhao and Chegini, 1999; Dimitriadis et al., 2000; Moller et al., 2001; Dominguez et al., 2008) . These proteins have also been detected in uterine Figure 3 Immunohistochemical analysis of FGF2 in cycling and first trimester pregnancy endometrium. Representative photomicrographs of n ¼ 5 tissues per group. FGF2 localized to stroma (S) in proliferative phase endometrium (Prolif) (A). In mid-late secretory phase endometrium (Sec) (B), FGF2 localized to both stroma (S), blood vessels (BV) and some glands (glandular epithelium, GE) but not others (arrowheads). In first trimester pregnancy endometrium (first trimester) (C), FGF2 localized intensely to the decidualized stroma (D) and GE. Negative controls (insets). Scale bars ¼ 50 mm. Semiquantitative scoring of immunoreactive FGF2 in glandular epithelium (D; *P , 0.001 versus prolif).
flushings (Makkar et al., 2006; Mikolajczyk et al., 2006; Hannan et al., 2009) confirming their secretion into the uterine cavity. Whilst in the uterine cavity, these cytokines and growth factors may act on the endometrial luminal epithelium in a paracrine manner to influence the expression of molecules such as cell adhesion molecules that facilitate receptivity and hence blastocyst attachment. They may also act directly on the blastocyst to facilitate its attachment and subsequent trophoblast growth and invasion by influencing the expression of cell adhesion molecules, other cytokines and proteases .
IL11 belongs to the IL6 family of cytokines that includes LIF, which is also regulated by hCG (Licht et al., 2001a; Perrier d'Hauterive et al., 2004) . Interestingly, both LIF and IL11-receptor alpha (RA) null mice are infertile due to a failure of blastocyst attachment or postimplantation defect, respectively (Stewart et al., 1992; Bilinski et al., 1998; Robb et al., 1998; Fouladi-Nashta et al., 2005) . IL11RA, like the LIF receptor is expressed by human endometrial glandular/ luminal epithelium during the secretory phase of the menstrual cycle (Sharkey et al., 1999; Dimitriadis et al., 2000) and in all trophoblast subtypes (Sharkey et al., 1999; Dimitriadis et al., 2003; Paiva et al., 2007) . Whether IL11RA is also expressed by the trophectoderm of the preimplantation human blastocyst is unknown. A potential role for IL11 in regulating human endometrial receptivity has been clearly demonstrated. IL11 stimulates primary hEEC adhesion to trophoblast cells and ECM matrices expressed by the blastocyst (Marwood et al., 2009) . Similar effects of LIF on hEEC adhesion have also been observed (Marwood et al., 2009) . IL11 and LIF also regulate trophoblast migration and invasion (Poehlmann et al., 2005; Horita et al., 2007; Paiva et al., 2009) . Interestingly, IL11, IL11RA and LIF expression in endometrial epithelium, during the window of implantation, is down-regulated in some infertile women, including those also with endometriosis (Tsai et al., 2000; Dimitriadis et al., 2006; Dimitriadis et al., 2007) .
GMCSF null mice exhibit a post-implantation fertility defect (Seymour et al., 1997) . The GMCSF receptor (GMRA) and the CXCL10 receptor (CXCR3) are expressed by human endometrial glandular/luminal epithelium (Zhao and Chegini, 1999; Hirota et al., 2006) , trophectodermal cells of the blastocyst (Robertson et al., 2001; Sjoblom et al., 2002; Dominguez et al., 2008) and also trophoblast cells (Jokhi et al., 1994; Dominguez et al., 2008) . Importantly, CXCL10 levels in uterine fluid are positively associated with IVF implantation rates (Boomsma et al., 2009) . While GMCSF promotes preimplantation blastocyst development and implantation rates in vitro (Spandorfer et al., 1998; Sjoblom et al., 2002) and regulates trophoblast differentiation (Garcia-Lloret et al., 1994) , CXCL10 stimulates blastocyst and trophoblast migration (Dominguez et al., 2008) . Their effects on endometrial epithelium and therefore receptivity remain to be determined.
Although FGF2 expression in human endometrium has been previously reported (Ferriani et al., 1993; Moller et al., 2001) , the results are conflicting. FGF2 expression was reported to vary across the menstrual cycle in the different endometrial cell types in one study (Moller et al., 2001) but not in the other (Ferriani et al., 1993) . Therefore, in this study, we aimed to verify the expression of FGF2 across the menstrual cycle and in first trimester pregnancy endometrium with a focus on the glandular epithelium, as it is this cell type that secretes FGF2 into the uterine cavity (where it can act on the endometrium/blastocyst) and is represented in our primary endometrial epithelial cell cultures. FGF2 increased in glandular epithelium as the menstrual cycle progressed and remained high in first trimester pregnancy endometrial epithelium in vivo. This expression pattern of FGF2 follows closely that of hCG in the local uterine microenvironment in cycling and pregnancy endometrium in vivo. Local hCG is maximally produced by the endometrial epithelium during the secretory phase (Zimmermann et al., 2009) , by the blastocyst in hCG enhances endometrial receptivity conception cycles prior to implantation (Lopata and Hay, 1989) and by trophoblast during first trimester pregnancy (Hoshina et al., 1985) . Hence the rise in FGF2 during the secretory phase may be due to endometrial-derived hCG. Surprisingly, in contrast with what is seen in vivo, under the specified culture conditions, primary hEEC did not produce detectable levels of hCG.
The FGF2 receptors include FGFR1 and FGFR2. FGFR1 is expressed in glandular and luminal epithelium maximally in the late proliferative and secretory phase whereas FGFR2 is expressed in glandular epithelium with little variation throughout the menstrual cycle (Moller et al., 2001 ). In the current study, we showed for the first time that FGF2 is biologically active in ECC1 cells. In these cells, which represent a luminal epithelial phenotype, FGF2 was capable of activating downstream mediators of the MAPK signalling pathway (i.e. ERK1/2) as previously demonstrated in other cell types (Gentilini et al., 2007) . FGF2 also exhibited a biological role in these cells stimulating ECC-1 cell adhesion to matrices such as FN and collagen IV normally expressed by the trophectoderm of the blastocyst (Thorsteinsdottir, 1992; Shimomura et al., 2006) . These findings suggest a plausible role for FGF2 in enhancing endometrial receptivity to facilitate blastocyst attachment during implantation. Further studies using polarized primary hEEC (i.e. fully representative of luminal epithelium) are required to verify the biological effects of FGF2 in these cells. Although, there is no data regarding the expression of FGF2 receptors by the human blastocyst, these are expressed by mouse blastocysts and FGF2 regulates mouse blastocyst attachment and trophoblast function (Taniguchi et al., 1998) .
The effects of hCG were stimulatory for all six cytokines/growth factors identified as being regulated by hCG in this study. Given that these factors have roles in either enhancing receptivity, blastocyst attachment and/or trophoblast function, it is likely that by stimulating the production of these, hCG facilitates the establishment of a receptive environment.
The intracellular pathways involved during hCG-mediated up-regulation of the factors identified in this study remain to be identified. Recently, prokineticin 1, which along with its receptor is maximally expressed in human endometrial epithelium during the secretory phase of the cycle, has been demonstrated to regulate expression of both LIF and IL11 mRNA (Evans et al., 2008) and to act as an intermediate in hCG regulation of LIF protein (Evans et al., 2009) . Whether the prokineticins are involved in hCG regulation of other cytokines and growth factors requires further investigation. Other studies suggest that the effects of hCG may be mediated by increased cyclooxygenase (COX) 2/prostaglandin E2 (PGE2) production either in a cAMP-dependent (primary human EECs) (Zhou et al., 1999) or -independent (Banerjee et al., 2009 ) (hEEC line) manner.
The present study was limited to the investigation of only 44 cytokines and growth factors; 42 is the maximum number of analytes that can reliably be analysed using Milliplex TM Luminex TM technology. These multiplex immunoassays allow the advantage of enabling multiple markers to be quantified simultaneously in a small sample volume (de Jager et al., 2003; Boomsma et al., 2009) . We separately measured LIF and IL11, which are of special interest in our laboratory, using the same Luminex TM technology. Proteomic studies investigating the entire secretome of hEEC and its regulation by hCG may identify further targets of hCG. Although hCG is produced by hEEC in vivo (Zimmermann et al., 2009) , under the culture conditions used in this study (i.e. serum-free) no endogenous hCG was secreted by primary hEEC. This maybe due to the absence of necessary stimulatory factors currently unknown.
In conclusion, the findings in this study demonstrate a role for blastocyst and/or endometrial-derived hCG in facilitating endometrial receptivity during implantation, by regulating the secretion of cytokines and growth factors important during this time. These findings suggest that although receptivity may occur in the absence of a blastocyst, it may be further enhanced once a blastocyst is within the uterine cavity. Functional studies investigating the effect of adding exogenous hCG or conversely blocking hCG on blastocyst-hEEC interactions are required to further validate the role of hCG in endometrial receptivity.
Implantation failure remains a limiting factor in the success of assisted reproductive technology where 70% of embryos selected for transfer fail to implant and up to 50% of this failure is likely to result from a non-receptive endometrium (Norwitz et al., 2001) . Therefore, greater insight into the molecular mechanisms governing the preparation of the endometrium for implantation and its unique molecular signature may enable significant increases in pregnancy success rates.
